Platt, H. L., Cardona, J. F., Haranaka, M., Schwartz, H. I., Narejos Perez, S., Dowell, A., Chang, C., Dagan, R., Tamms, G. M., Sterling, T., Morgan, L., Shi, Y., Pedley, A., Musey, L. K., & Buchwald, U. K. (2022). a phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine, 40(1), 162–172. http://access.bl.uk/ark:/81055/vdc_100146760239.0x000046